Repurposing Colchicine in Treating Patients with COVID-19: A Systematic Review and Meta-Analysis

Coronavirus disease 2019 (COVID-19) had caused huge health losses worldwide. Several drugs had been applied to treat patients with COVID-19, and repurposing colchicine had been proposed for its anti-inflammatory properties via several pathways. In this systematic review, we evaluated the effects of colchicine treatment. From inception to May 31, 2021, databases, including PubMed, EMbase, medRxiv, and Research Square were searched, and 11 studies were enrolled. A total of 17,205 COVID-19 patients with male predominance (62.9%) were analyzed. Patients with colchicine treatment had a significantly lower risk of mortality (odds ratio (OR): 0.57, 95% confidence interval (CI): 0.38–0.87, I2: 72%; p < 0.01) and a non-significantly lower rate of mechanical ventilation (OR: 0.67, 95%CI: 0.39–1.15). The side effects were mild and not significantly different (OR: 2.03, 95%CI: 0.51–8.09). Subgroup analysis with randomized controlled trials showed no statistically significant difference in the mortality (OR: 0.80, 95%CI: 0.44–1.46, I2: 33%; p = 0.22). In conclusion, our meta-analysis found that colchicine treatment was associated with a significantly lower risk of mortality in patients with COVID-19. However, this benefit was not observed in the subgroup analysis of randomized controlled trials. Further randomized controlled studies are required to confirm the potential benefits of colchicine treatment.

[1]  D. Gaudet,et al.  Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial , 2021, The Lancet Respiratory Medicine.

[2]  M. Landray,et al.  Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial , 2021, The Lancet Respiratory Medicine.

[3]  M. Bilal,et al.  Diverse Immunological Factors Influencing Pathogenesis in Patients with COVID-19: A Review on Viral Dissemination, Immunotherapeutic Options to Counter Cytokine Storm and Inflammatory Responses , 2021, Pathogens.

[4]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, BMJ.

[5]  A. Kurniawan,et al.  Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID‐19): A systematic review and meta‐analysis , 2021, Clinical and experimental pharmacology & physiology.

[6]  S. Mattar,et al.  Clinical outcomes of patients hospitalized for COVID-19 and evidence-based on the pharmacological management reduce mortality in a region of the Colombian Caribbean , 2021, Journal of Infection and Public Health.

[7]  B. Mégarbane,et al.  Oral corticoid, aspirin, anticoagulant, colchicine, and furosemide to improve the outcome of hospitalized COVID-19 patients - the COCAA-COLA cohort study , 2021, Journal of Infection.

[8]  F. Cunha,et al.  Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial , 2021, RMD Open.

[9]  M. Pinzón,et al.  Clinical outcome of patients with COVID-19 Pneumonia treated with corticosteroids and colchicine in Colombia , 2020, Annals of clinical microbiology and antimicrobials.

[10]  S. Jog,et al.  A Retrospective Observational Study of Hypoxic COVID-19 Patients Treated with Immunomodulatory Drugs in a Tertiary Care Hospital , 2020, Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine.

[11]  S. Chilimuri,et al.  A Case Control Study to Evaluate the Impact of Colchicine on Patients Admitted to the Hospital with Moderate to Severe COVID-19 Infection , 2020, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.

[12]  S. Weng,et al.  Taiwan Government-Guided Strategies Contributed to Combating and Controlling COVID-19 Pandemic , 2020, Frontiers in Public Health.

[13]  J. P. de Rivero Vaccari,et al.  The Inflammasome in Times of COVID-19 , 2020, Frontiers in Immunology.

[14]  Arthur S Slutsky,et al.  Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. , 2020, JAMA.

[15]  B. Firestein,et al.  Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19 , 2020, Journal of clinical medicine.

[16]  N. Chiu,et al.  One-Seventh of Patients with COVID-19 Had Olfactory and Gustatory Abnormalities as Their Initial Symptoms: A Systematic Review and Meta-Analysis , 2020, Life.

[17]  N. Chiu,et al.  Clinical features of neonates born to mothers with coronavirus disease-2019: A systematic review of 105 neonates , 2020, Journal of Microbiology, Immunology and Infection.

[18]  M. Cotelli,et al.  Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome , 2020, Annals of the Rheumatic Diseases.

[19]  B. Firestein,et al.  Colchicine in COVID-19: an Old Drug, New Use , 2020, Current Pharmacology Reports.

[20]  J. Tardif,et al.  Colchicine reduces lung injury in experimental acute respiratory distress syndrome , 2020, PloS one.

[21]  A. T. Te Velde,et al.  Severe COVID-19: NLRP3 Inflammasome Dysregulated , 2020, Frontiers in Immunology.

[22]  T. Swartz,et al.  Targeting the NLRP3 Inflammasome in Severe COVID-19 , 2020, Frontiers in Immunology.

[23]  G. Dangas,et al.  Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019 , 2020, JAMA network open.

[24]  L. Dodd,et al.  Remdesivir for the Treatment of Covid-19 — Final Report , 2020, The New England journal of medicine.

[25]  A. Shah.  Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A Potential Drug Target in the Treatment of COVID-19 , 2020, Frontiers in Immunology.

[26]  R. Lorusso,et al.  COVID-19 and ECMO: the interplay between coagulation and inflammation—a narrative review , 2020, Critical Care.

[27]  Koichi Yuki,et al.  COVID-19 pathophysiology: A review , 2020, Clinical Immunology.

[28]  Amber Dance.  What is a cytokine storm? , 2020 .

[29]  N. Dalbeth,et al.  Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials , 2020, Arthritis Research & Therapy.

[30]  J. Ting,et al.  The NLRP3 inflammasome: molecular activation and regulation to therapeutics , 2019, Nature Reviews Immunology.

[31]  D. Celermajer,et al.  The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation. , 2017, Atherosclerosis.

[32]  V. Kraus,et al.  Colchicine--Update on mechanisms of action and therapeutic uses. , 2015, Seminars in arthritis and rheumatism.

[33]  D. Celermajer,et al.  Colchicine Acutely Suppresses Local Cardiac Production of Inflammatory Cytokines in Patients With an Acute Coronary Syndrome , 2015, Journal of the American Heart Association.

[34]  N. Dalbeth,et al.  Mechanism of action of colchicine in the treatment of gout. , 2014, Clinical therapeutics.

[35]  P. Tugwell,et al.  The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses , 2014 .

[36]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[37]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.